Dose-Finding Methods for Non-Binary Outcomes
Generate operating characteristics for finding the maximum tolerated d...
Generate operating characteristics for finding the maximum tolerated d...
Generate operating characteristics for finding the maximum tolerated d...
Generate operating characteristics for finding the maximum tolerated d...
Generate operating characteristics for finding the maximum tolerated d...
Generate operating characteristics for finding the maximum tolerated d...
Determine the dose for the next cohort of new patients for single-agen...
Determine the dose for the next cohort of new patients for single-agen...
Determine the dose for the next cohort of new patients of binary endpo...
Determine the dose for the next cohort of new patients using Inanova d...
Determine the dose for the next cohort of new patients based on equiva...
Determine the dose for the next cohort of new patients using Quasi-CRM...
Select the maximum tolerated dose (MTD) for single agent trials using ...
Select the maximum tolerated dose (MTD) defined by Toxicity Burden (TB...
Select the maximum tolerated dose (MTD) of binary endpoint for single ...
Select the maximum tolerated dose (MTD) for single agent trials of con...
Select the maximum tolerated dose (MTD)-defined by equivalent score (E...
Select the maximum tolerated dose (MTD) using Quasi-CRM design
In many phase I trials, the design goal is to find the dose associated with a certain target toxicity rate. In some trials, the goal can be to find the dose with a certain weighted sum of rates of various toxicity grades. For others, the goal is to find the dose with a certain mean value of a continuous response. This package provides the setup and calculations needed to run a dose-finding trial with non-binary endpoints and performs simulations to assess design’s operating characteristics under various scenarios. Three dose finding designs are included in this package: unified phase I design (Ivanova et al. (2009) <doi:10.1111/j.1541-0420.2008.01045.x>), Quasi-CRM/Robust-Quasi-CRM (Yuan et al. (2007) <doi:10.1111/j.1541-0420.2006.00666.x>, Pan et al. (2014) <doi:10.1371/journal.pone.0098147>) and generalized BOIN design (Mu et al. (2018) <doi:10.1111/rssc.12263>). The toxicity endpoints can be handled with these functions including equivalent toxicity score (ETS), total toxicity burden (TTB), general continuous toxicity endpoints, with incorporating ordinal grade toxicity information into dose-finding procedure. These functions allow customization of design characteristics to vary sample size, cohort sizes, target dose-limiting toxicity (DLT) rates, discrete or continuous toxicity score, and incorporate safety and/or stopping rules.